Moderna (MRNA.O) shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck (MRK.N) showed positive response in an early-stage trial in patients with a type of head and neck cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,